The Provigil Vigil
This article was originally published in RPM Report
Executive Summary
After the Plavix debacle, the Federal Trade Commission, and investors, are wondering about Cephalon's lifeblood Provigil. Cephalon says there's nothing to worry about.
You may also be interested in...
Generic Plavix: As Bristol Swoons, Broad Implications
The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.
Unsettling Developments for Plavix
Bristol-Myers Squibb Co. and Sanofi-Aventis are anxiously awaiting the outcome of an antitrust review of a proposed patent settlement with Apotex Inc. over the timing of a generic launch of clopidogrel (Plavix). They have reason to sweat: it sounds like the Federal Trade Commission is spoiling for a fight.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.